- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Monoclonal antibodies (mAbs) Biosimilars market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Monoclonal antibodies (mAbs) Biosimilars market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Anti-Cancer accounting for % of the Monoclonal antibodies (mAbs) Biosimilars global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Erythropoietin (EPO) segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Monoclonal antibodies (mAbs) Biosimilars include Biocon, Celltrion, Dr. Reddy's Laboratories, Hospira, and 3SBio, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Monoclonal antibodies (mAbs) Biosimilars market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Erythropoietin (EPO)
Human Growth Hormone (HGH)
Granulocyte- Colony Stimulating Factor (G-CSF)
Monoclonal Antibody (mAb)
Insulin
Interferon (IFN)
Others
Market segment by Application, can be divided into
Anti-Cancer
Anti-Inflammatory/Autoimmune
Market segment by players, this report covers
Biocon
Celltrion
Dr. Reddy's Laboratories
Hospira
3SBio
Accord Healthcare
AET Biotech
Allergan
Amega Biotech
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Monoclonal antibodies (mAbs) Biosimilars product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Monoclonal antibodies (mAbs) Biosimilars, with revenue, gross margin and global market share of Monoclonal antibodies (mAbs) Biosimilars from 2019 to 2022.
Chapter 3, the Monoclonal antibodies (mAbs) Biosimilars competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Monoclonal antibodies (mAbs) Biosimilars market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Monoclonal antibodies (mAbs) Biosimilars research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1 Market Overview
1.1 Product Overview and Scope of Monoclonal antibodies (mAbs) Biosimilars
1.2 Classification of Monoclonal antibodies (mAbs) Biosimilars by Type
1.2.1 Overview: Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type in 2021
1.2.3 Erythropoietin (EPO)
1.2.4 Human Growth Hormone (HGH)
1.2.5 Granulocyte- Colony Stimulating Factor (G-CSF)
1.2.6 Monoclonal Antibody (mAb)
1.2.7 Insulin
1.2.8 Interferon (IFN)
1.2.9 Others
1.3 Global Monoclonal antibodies (mAbs) Biosimilars Market by Application
1.3.1 Overview: Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Anti-Cancer
1.3.3 Anti-Inflammatory/Autoimmune
1.4 Global Monoclonal antibodies (mAbs) Biosimilars Market Size & Forecast
1.5 Global Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast by Region
1.5.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region, (2017-2022)
1.5.3 North America Monoclonal antibodies (mAbs) Biosimilars Market Size and Prospect (2017-2028)
1.5.4 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size and Prospect (2017-2028)
1.5.6 South America Monoclonal antibodies (mAbs) Biosimilars Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Monoclonal antibodies (mAbs) Biosimilars Market Drivers
1.6.2 Monoclonal antibodies (mAbs) Biosimilars Market Restraints
1.6.3 Monoclonal antibodies (mAbs) Biosimilars Trends Analysis
2 Company Profiles
2 Company Profiles
2.1 Biocon
2.1.1 Biocon Details
2.1.2 Biocon Major Business
2.1.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.1.4 Biocon Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Biocon Recent Developments and Future Plans
2.2 Celltrion
2.2.1 Celltrion Details
2.2.2 Celltrion Major Business
2.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.2.4 Celltrion Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Celltrion Recent Developments and Future Plans
2.3 Dr. Reddy's Laboratories
2.3.1 Dr. Reddy's Laboratories Details
2.3.2 Dr. Reddy's Laboratories Major Business
2.3.3 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.3.4 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Dr. Reddy's Laboratories Recent Developments and Future Plans
2.4 Hospira
2.4.1 Hospira Details
2.4.2 Hospira Major Business
2.4.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.4.4 Hospira Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Hospira Recent Developments and Future Plans
2.5 3SBio
2.5.1 3SBio Details
2.5.2 3SBio Major Business
2.5.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.5.4 3SBio Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 3SBio Recent Developments and Future Plans
2.6 Accord Healthcare
2.6.1 Accord Healthcare Details
2.6.2 Accord Healthcare Major Business
2.6.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.6.4 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Accord Healthcare Recent Developments and Future Plans
2.7 AET Biotech
2.7.1 AET Biotech Details
2.7.2 AET Biotech Major Business
2.7.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.7.4 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 AET Biotech Recent Developments and Future Plans
2.8 Allergan
2.8.1 Allergan Details
2.8.2 Allergan Major Business
2.8.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.8.4 Allergan Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Allergan Recent Developments and Future Plans
2.9 Amega Biotech
2.9.1 Amega Biotech Details
2.9.2 Amega Biotech Major Business
2.9.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.9.4 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Amega Biotech Recent Developments and Future Plans
3 Market Competition, by Players
3 Market Competition, by Players
3.1 Global Monoclonal antibodies (mAbs) Biosimilars Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Monoclonal antibodies (mAbs) Biosimilars Players Market Share in 2021
3.2.2 Top 10 Monoclonal antibodies (mAbs) Biosimilars Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Monoclonal antibodies (mAbs) Biosimilars Players Head Office, Products and Services Provided
3.4 Monoclonal antibodies (mAbs) Biosimilars Mergers & Acquisitions
3.5 Monoclonal antibodies (mAbs) Biosimilars New Entrants and Expansion Plans
4 Market Size Segment by Type
4 Market Size Segment by Type
4.1 Global Monoclonal antibodies (mAbs) Biosimilars Revenue and Market Share by Type (2017-2022)
4.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5 Market Size Segment by Application
5.1 Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2017-2022)
5.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6 North America by Country, by Type, and by Application
6.1 North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2028)
6.2 North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2028)
6.3 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country
6.3.1 North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2017-2028)
6.3.2 United States Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
6.3.3 Canada Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
6.3.4 Mexico Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7 Europe by Country, by Type, and by Application
7.1 Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2028)
7.2 Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2028)
7.3 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country
7.3.1 Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2017-2028)
7.3.2 Germany Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
7.3.3 France Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
7.3.5 Russia Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
7.3.6 Italy Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2028)
8.2 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2028)
8.3 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region
8.3.1 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Region (2017-2028)
8.3.2 China Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
8.3.3 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
8.3.4 South Korea Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
8.3.5 India Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
8.3.7 Australia Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9 South America by Country, by Type, and by Application
9.1 South America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2028)
9.2 South America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2028)
9.3 South America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country
9.3.1 South America Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2017-2028)
9.3.2 Brazil Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
9.3.3 Argentina Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2028)
10.2 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2028)
10.3 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country
10.3.1 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2017-2028)
10.3.2 Turkey Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
10.3.4 UAE Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
11 Research Findings and Conclusion
12 Appendix
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Monoclonal antibodies (mAbs) Biosimilars Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Monoclonal antibodies (mAbs) Biosimilars Revenue (USD Million) by Region (2017-2022)
Table 5. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Region (2023-2028)
Table 6. Biocon Corporate Information, Head Office, and Major Competitors
Table 7. Biocon Major Business
Table 8. Biocon Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
Table 9. Biocon Monoclonal antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Celltrion Corporate Information, Head Office, and Major Competitors
Table 11. Celltrion Major Business
Table 12. Celltrion Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
Table 13. Celltrion Monoclonal antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Dr. Reddy's Laboratories Corporate Information, Head Office, and Major Competitors
Table 15. Dr. Reddy's Laboratories Major Business
Table 16. Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
Table 17. Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Hospira Corporate Information, Head Office, and Major Competitors
Table 19. Hospira Major Business
Table 20. Hospira Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
Table 21. Hospira Monoclonal antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. 3SBio Corporate Information, Head Office, and Major Competitors
Table 23. 3SBio Major Business
Table 24. 3SBio Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
Table 25. 3SBio Monoclonal antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Accord Healthcare Corporate Information, Head Office, and Major Competitors
Table 27. Accord Healthcare Major Business
Table 28. Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
Table 29. Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. AET Biotech Corporate Information, Head Office, and Major Competitors
Table 31. AET Biotech Major Business
Table 32. AET Biotech Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
Table 33. AET Biotech Monoclonal antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Allergan Corporate Information, Head Office, and Major Competitors
Table 35. Allergan Major Business
Table 36. Allergan Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
Table 37. Allergan Monoclonal antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Amega Biotech Corporate Information, Head Office, and Major Competitors
Table 39. Amega Biotech Major Business
Table 40. Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
Table 41. Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Global Monoclonal antibodies (mAbs) Biosimilars Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 43. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 44. Breakdown of Monoclonal antibodies (mAbs) Biosimilars by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Monoclonal antibodies (mAbs) Biosimilars Players Head Office, Products and Services Provided
Table 46. Monoclonal antibodies (mAbs) Biosimilars Mergers & Acquisitions in the Past Five Years
Table 47. Monoclonal antibodies (mAbs) Biosimilars New Entrants and Expansion Plans
Table 48. Global Monoclonal antibodies (mAbs) Biosimilars Revenue (USD Million) by Type (2017-2022)
Table 49. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Share by Type (2017-2022)
Table 50. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Forecast by Type (2023-2028)
Table 51. Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2022)
Table 52. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Forecast by Application (2023-2028)
Table 53. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2022) & (USD Million)
Table 54. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2023-2028) & (USD Million)
Table 55. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2022) & (USD Million)
Table 56. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2023-2028) & (USD Million)
Table 57. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2017-2022) & (USD Million)
Table 58. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2023-2028) & (USD Million)
Table 59. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2022) & (USD Million)
Table 60. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2023-2028) & (USD Million)
Table 61. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2022) & (USD Million)
Table 62. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2023-2028) & (USD Million)
Table 63. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2017-2022) & (USD Million)
Table 64. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2023-2028) & (USD Million)
Table 65. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2022) & (USD Million)
Table 66. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2023-2028) & (USD Million)
Table 67. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2022) & (USD Million)
Table 68. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2023-2028) & (USD Million)
Table 69. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Region (2017-2022) & (USD Million)
Table 70. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Region (2023-2028) & (USD Million)
Table 71. South America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2022) & (USD Million)
Table 72. South America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2023-2028) & (USD Million)
Table 73. South America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2022) & (USD Million)
Table 74. South America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2023-2028) & (USD Million)
Table 75. South America Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2017-2022) & (USD Million)
Table 76. South America Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2023-2028) & (USD Million)
Table 77. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2022) & (USD Million)
Table 78. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2023-2028) & (USD Million)
Table 79. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2022) & (USD Million)
Table 80. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2023-2028) & (USD Million)
Table 81. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2017-2022) & (USD Million)
Table 82. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Monoclonal antibodies (mAbs) Biosimilars Picture
Figure 2. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type in 2021
Figure 3. Erythropoietin (EPO)
Figure 4. Human Growth Hormone (HGH)
Figure 5. Granulocyte- Colony Stimulating Factor (G-CSF)
Figure 6. Monoclonal Antibody (mAb)
Figure 7. Insulin
Figure 8. Interferon (IFN)
Figure 9. Others
Figure 10. Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application in 2021
Figure 11. Anti-Cancer Picture
Figure 12. Anti-Inflammatory/Autoimmune Picture
Figure 13. Global Monoclonal antibodies (mAbs) Biosimilars Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 14. Global Monoclonal antibodies (mAbs) Biosimilars Revenue and Forecast (2017-2028) & (USD Million)
Figure 15. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Region (2017-2028)
Figure 16. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Region in 2021
Figure 17. North America Monoclonal antibodies (mAbs) Biosimilars Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. South America Monoclonal antibodies (mAbs) Biosimilars Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue (USD Million) and Growth Rate (2017-2028)
Figure 22. Monoclonal antibodies (mAbs) Biosimilars Market Drivers
Figure 23. Monoclonal antibodies (mAbs) Biosimilars Market Restraints
Figure 24. Monoclonal antibodies (mAbs) Biosimilars Market Trends
Figure 25. Biocon Recent Developments and Future Plans
Figure 26. Celltrion Recent Developments and Future Plans
Figure 27. Dr. Reddy's Laboratories Recent Developments and Future Plans
Figure 28. Hospira Recent Developments and Future Plans
Figure 29. 3SBio Recent Developments and Future Plans
Figure 30. Accord Healthcare Recent Developments and Future Plans
Figure 31. AET Biotech Recent Developments and Future Plans
Figure 32. Allergan Recent Developments and Future Plans
Figure 33. Amega Biotech Recent Developments and Future Plans
Figure 34. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Share by Players in 2021
Figure 35. Monoclonal antibodies (mAbs) Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 36. Global Top 3 Players Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share in 2021
Figure 37. Global Top 10 Players Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share in 2021
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 39. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Share by Type in 2021
Figure 40. Global Monoclonal antibodies (mAbs) Biosimilars Market Share Forecast by Type (2023-2028)
Figure 41. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Share by Application in 2021
Figure 42. Global Monoclonal antibodies (mAbs) Biosimilars Market Share Forecast by Application (2023-2028)
Figure 43. North America Monoclonal antibodies (mAbs) Biosimilars Sales Market Share by Type (2017-2028)
Figure 44. North America Monoclonal antibodies (mAbs) Biosimilars Sales Market Share by Application (2017-2028)
Figure 45. North America Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Country (2017-2028)
Figure 46. United States Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Canada Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Mexico Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Europe Monoclonal antibodies (mAbs) Biosimilars Sales Market Share by Type (2017-2028)
Figure 50. Europe Monoclonal antibodies (mAbs) Biosimilars Sales Market Share by Application (2017-2028)
Figure 51. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Country (2017-2028)
Figure 52. Germany Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. France Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. United Kingdom Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Russia Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Italy Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Sales Market Share by Type (2017-2028)
Figure 58. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Sales Market Share by Application (2017-2028)
Figure 59. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Region (2017-2028)
Figure 60. China Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Japan Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South Korea Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. India Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Australia Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South America Monoclonal antibodies (mAbs) Biosimilars Sales Market Share by Type (2017-2028)
Figure 67. South America Monoclonal antibodies (mAbs) Biosimilars Sales Market Share by Application (2017-2028)
Figure 68. South America Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Country (2017-2028)
Figure 69. Brazil Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Sales Market Share by Type (2017-2028)
Figure 72. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Sales Market Share by Application (2017-2028)
Figure 73. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Country (2017-2028)
Figure 74. Turkey Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. UAE Monoclonal antibodies (mAbs) Biosimilars Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
